Oral Micronized Progesterone and Rivaroxaban Interaction

Why This Combination Comes Up in Clinical Practice

Women on rivaroxaban for atrial fibrillation, prior pulmonary embolism, or deep vein thrombosis frequently reach menopause and develop vasomotor symptoms that warrant hormone replacement therapy. Their prescribers then face a practical question: can you safely add oral micronized progesterone for endometrial protection while the patient is already anticoagulated? The answer requires understanding two separate dimensions of risk. One is pharmacokinetic (does progesterone change rivaroxaban blood levels?). The other is pharmacodynamic (does adding a hormone shift the clotting balance in a patient who is anticoagulated for good reason?).

Rivaroxaban is a factor Xa inhibitor approved by the FDA in 2011 for stroke prevention in non-valvular atrial fibrillation, treatment of DVT/PE, and secondary VTE prophylaxis [1]. Oral micronized progesterone (brand name Prometrium) is bioidentical progesterone prescribed at 100 to 200 mg nightly, most commonly to protect the endometrium in women taking estrogen-based HRT [2]. Both drugs pass through the liver, and both interact with the CYP3A4 enzyme system, which is the metabolic pathway that generates the most drug-interaction questions in clinical pharmacology.

CYP3A4 and P-Glycoprotein: The Pharmacokinetic Overlap

Rivaroxaban is metabolized by CYP3A4, CYP2J2, and CYP-independent hydrolysis, and it is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) [1]. Strong dual inhibitors of CYP3A4 and P-gp (ketoconazole, ritonavir) increase rivaroxaban AUC by up to 160%, which is why the Xarelto prescribing information lists these as contraindicated combinations [1]. Oral micronized progesterone is also a CYP3A4 substrate. It does not, however, function as a potent inhibitor or inducer of this enzyme at standard 100 to 200 mg doses [2].

In vitro data show that progesterone can weakly inhibit CYP3A4 at supratherapeutic concentrations, but the IC50 values exceed plasma levels achieved with 200 mg oral dosing by a wide margin [3]. This means the pharmacokinetic interaction is theoretical rather than clinical. No published study has demonstrated a measurable change in rivaroxaban peak concentration (Cmax) or area under the curve (AUC) when co-administered with oral micronized progesterone at HRT doses. The Lexicomp drug interaction database rates this pair as "minor" severity with a recommendation to monitor rather than avoid [4].

P-glycoprotein transport adds a second layer. Rivaroxaban depends on P-gp for intestinal absorption and renal secretion [1]. Progesterone has been identified as a weak P-gp substrate in cell-line studies, but it does not meaningfully compete for transport at clinically relevant concentrations [3]. Strong P-gp inhibitors like dronedarone raise rivaroxaban levels enough to warrant dose reduction. Progesterone does not fall into this category.

The Pharmacodynamic Concern: Hormones and Clotting Risk

The more relevant interaction is not metabolic. It is biological. Exogenous sex hormones influence coagulation factor synthesis, fibrinolysis, and platelet activation. The Women's Health Initiative (WHI) demonstrated that combined estrogen plus medroxyprogesterone acetate (MPA) increased VTE risk by 2.1-fold compared to placebo (HR 2.06, 95% CI 1.57 to 2.70) [5]. That finding reshaped HRT prescribing for a generation.

Oral micronized progesterone appears to carry a substantially lower thrombotic risk than MPA. The E3N French cohort study (N=80,308 postmenopausal women) found that estrogen combined with micronized progesterone did not significantly increase VTE risk (OR 0.9, 95% CI 0.6 to 1.5), while estrogen plus synthetic progestins raised risk significantly (OR 1.4, 95% CI 1.1 to 1.8) [6]. The ESTHER case-control study confirmed this pattern, reporting no significant VTE increase with transdermal estradiol plus micronized progesterone compared to non-users [7].

"Micronized progesterone is the progestogen of choice when VTE risk is a clinical consideration," stated the 2022 North American Menopause Society (NAMS) position statement on hormone therapy [8]. This preference is reflected in prescribing patterns across North America and Europe, where clinicians increasingly select micronized progesterone over MPA or norethindrone for women who have thrombotic risk factors.

For the patient already on rivaroxaban, the question becomes whether adding even a modest prothrombotic signal makes clinical sense. The answer depends on the indication for anticoagulation, the duration of therapy, and the severity of menopausal symptoms.

Severity Ratings Across DDI Databases

Drug interaction databases do not uniformly classify this pair. Lexicomp assigns a "C" rating (monitor therapy) to the progesterone-rivaroxaban combination, noting the theoretical pharmacokinetic overlap without documented clinical events [4]. Clinical Pharmacology (Elsevier) rates the interaction as "minor" with low evidence quality. Micromedex does not list a direct monograph for this specific pair but flags a class-level interaction between "hormonal agents" and "anticoagulants" as moderate.

The FDA-approved labeling for Prometrium includes a general warning about VTE risk with progestins but does not specifically address DOAC co-administration [2]. The Xarelto label lists strong CYP3A4/P-gp inhibitors and inducers as clinically significant interactions. Progesterone does not appear in the Xarelto interaction table [1].

This discordance across databases is typical of drug pairs where the theoretical mechanism exists but the clinical evidence is absent. No case reports of rivaroxaban toxicity or failure attributed to concurrent progesterone use have been published in PubMed as of May 2026.

Who Needs Extra Monitoring

Not every patient on this combination needs the same level of surveillance. Risk stratification matters. Women taking rivaroxaban for a first provoked DVT (e.g., post-surgical) who are now beyond their initial treatment period carry a different risk profile than women with unprovoked recurrent PE or antiphospholipid syndrome.

Patients who warrant closer monitoring include those with:

• Factor V Leiden or prothrombin G20210A mutation plus a history of VTE, where even small hormonal shifts in coagulation may be clinically relevant
• Active cancer-associated thrombosis, where rivaroxaban is being used per the SELECT-D trial protocol (rivaroxaban 15 mg BID for 21 days, then 20 mg daily) and hormonal status is changing [9]
• Antiphospholipid syndrome, where the TRAPS trial demonstrated harm with rivaroxaban versus warfarin, and adding hormonal agents introduces additional complexity [10]
• Renal impairment (CrCl 15 to 50 mL/min), which alters rivaroxaban clearance and could amplify any theoretical pharmacokinetic interaction

For these higher-risk patients, checking a one-time anti-factor Xa level (rivaroxaban-calibrated) 2 to 4 weeks after starting progesterone provides reassurance that drug levels remain in the expected range (peak 141 to 326 ng/mL for the 20 mg dose) [11].

Practical Dose and Timing Guidance

Standard dosing for endometrial protection is oral micronized progesterone 200 mg nightly for 12 to 14 days per calendar month (cyclic regimen) or 100 mg nightly continuously [2]. Rivaroxaban dosing varies by indication: 20 mg daily with food for atrial fibrillation, 15 mg BID for 21 days followed by 20 mg daily for acute VTE, and 10 mg daily for extended VTE prophylaxis [1].

No dose adjustment of either drug is required when used together. Timing separation is unnecessary from a pharmacokinetic standpoint, though both drugs are commonly taken in the evening (progesterone causes drowsiness; rivaroxaban's 20 mg AF dose is taken with dinner). Taking them at the same time with food is acceptable and may improve adherence.

The 2017 American College of Cardiology expert consensus document on periprocedural management of anticoagulation noted that CYP3A4 substrates without inhibitory or inducing properties do not require rivaroxaban dose modification [12]. Oral micronized progesterone at 100 to 200 mg fits this profile.

Switching from Warfarin to Rivaroxaban While on Progesterone

Some women are already on warfarin plus progesterone when the discussion of switching to a DOAC arises. This transition has a specific clinical nuance. Warfarin interacts with progesterone differently. Warfarin is metabolized primarily by CYP2C9, not CYP3A4, so the metabolic overlap with progesterone is minimal through a different pathway. The INR-based monitoring of warfarin, however, provides visible reassurance that anticoagulation intensity is stable.

When switching to rivaroxaban, that visible metric disappears. Rivaroxaban does not require routine coagulation monitoring, and standard PT/INR tests do not reliably reflect rivaroxaban activity [1]. For patients and clinicians accustomed to checking INR every 4 weeks, this loss of a measurable endpoint can create anxiety, especially when a hormonal agent is in the mix.

The EINSTEIN-CHOICE trial (N=3,396) established that rivaroxaban 20 mg or 10 mg daily was superior to aspirin for extended VTE prevention with similar major bleeding rates [13]. Subgroup analysis did not identify hormone therapy as a modifier of rivaroxaban efficacy, though the trial was not powered for this comparison.

A reasonable approach for the transitioning patient: obtain a rivaroxaban-calibrated anti-factor Xa level at steady state (day 5 to 7 after starting rivaroxaban, drawn 2 to 4 hours post-dose) to confirm expected drug exposure, then recheck once at 3 months.

What About Transdermal Progesterone?

Patients sometimes ask whether switching to transdermal or vaginal progesterone (e.g., Crinone 8% gel, compounded progesterone cream) eliminates the interaction concern entirely. From a pharmacokinetic perspective, non-oral routes bypass first-pass hepatic metabolism, which means less CYP3A4 involvement and lower systemic progesterone levels [14]. From a pharmacodynamic perspective, the VTE signal is already negligible with oral micronized progesterone at HRT doses, so the marginal benefit of switching routes for interaction avoidance alone is minimal.

Vaginal progesterone achieves high endometrial tissue concentrations with lower serum levels (the "uterine first-pass effect"), making it an option for women who want maximal endometrial protection with minimal systemic hormone exposure [14]. This route may appeal to patients with multiple thrombotic risk factors who want to minimize every possible contributor to clotting risk, even when rivaroxaban is providing active anticoagulation.

The REPLENISH trial (N=1,845) evaluated the combination of conjugated estrogens with bazedoxifene (a SERM) as an alternative to estrogen-plus-progestogen HRT, and reported a VTE rate of 0.36 per 1,000 woman-years versus 0.36 for placebo [15]. This offers another option for women on DOACs who want menopausal symptom relief without any progestogen at all, though it requires an intact discussion of the different benefit-risk profile.

Patient Counseling Points

Women prescribed both medications should know three things. First, this combination is used in clinical practice without documented cases of interaction-related harm. Second, the reason their prescriber may want a follow-up blood test is precautionary, not because a dangerous reaction is expected. Third, they should report any unusual bleeding (heavy periods, nosebleeds lasting over 20 minutes, blood in urine or stool) or any signs of clotting (leg swelling, sudden shortness of breath, chest pain) promptly.

Dr. JoAnn Manson, professor of medicine at Harvard Medical School and principal investigator of the WHI hormone trials, noted in a 2020 review: "The type of progestogen matters. Micronized progesterone and transdermal estradiol represent the safer hormonal options for women with cardiovascular and thrombotic risk factors" [16]. This applies directly to the clinical scenario of a woman on rivaroxaban who needs endometrial protection.

Patients should also be aware that grapefruit juice is a moderate CYP3A4 inhibitor. While a single glass is unlikely to cause problems, regular large-volume consumption (more than 1 liter daily) could theoretically raise both progesterone and rivaroxaban levels. The Xarelto label does not contraindicate grapefruit, but it is worth mentioning during counseling [1].

The rivaroxaban 10 mg extended prophylaxis dose (used after initial VTE treatment) has a wider therapeutic window than the 20 mg dose, providing additional safety margin if any minor pharmacokinetic interaction were to occur at the CYP3A4 level.